Tumor-Derived FGF19

Part of paid clinical trials in Orlando, Florida.

Sponsor
University of Central Florida
Study ID
NCT06068257
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Study Details

Identify and test thresholds, specificity and sensitivity for a potential cancer associated biomarker protein, FGF19, (and associated markers) for detection in human blood in the blood of breast and colorectal in cancer patients, and see if occurs at higher rates than healthy controls

Key Dates

Start date
Jun 6, 2023
Status verified
Dec 2024
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025

Study Design

Enrollment
210 participants (estimated)

Primary Outcome Measure

To Identify and test thresholds, specificity and sensitivity for FGF19, (and associated markers) for detection in human blood of breast and colorectal in cancer patients, and see if occurs at higher rates than healthy controls. [ Time Frame: 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Burnett School Biomedical SciencesOrlandoFlorida32816
Amoy Fraser, PhD, CCRP, PMP
[email protected]
407-266-8742
Erica Martin, B.S.
[email protected]
407-266-8742

Find similar trials in Orlando, FL

By condition
Breast cancerColorectal cancer
By specialty
OncologyBreast oncologyWomen's healthGI oncology
By research site
Burnett School Biomedical Sciences· Orlando, FL

Related Studies